Study analysis · Cureus · 2022
Poop transplants reversed memory loss in Alzheimer's patients—but the proof is still in the toilet.
This review of 13 studies suggests that transplanting healthy gut bacteria from a donor can improve memory and thinking in Alzheimer's patients, but the evidence is very weak.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
Imagine you hear stories about a new treatment helping some mice and two people feel better. That's what this study is—a collection of stories. It might suggest the treatment could help, but it's not a strong proof because there's no big experiment. So we can say 'it might help' but not 'it definitely helps'.
What’s the bottom line?
Alzheimer's disease is a brain problem that gets worse over time. Some scientists think that the bacteria in our gut (the 'gut microbiome') might affect the brain. They studied whether putting healthy poop from a donor into an Alzheimer's patient (called FMT) could help. This review looked at 13 studies, mostly in mice and a few people.
How strong is this study?
The researchers looked for all the stories carefully, but most of them are not very reliable—like stories from mice or just two people. That means we can't trust the results very much. We need bigger studies with more people to be sure.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
0 / 100
- Randomizationnot randomized
- Blindingnot blinded
- Control groupno control group
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 528 / 100
Probability of being correct
Systematic reviews and meta-analyses of cohort studies. They sit above a single cohort study but below a single randomized trial, because the underlying evidence is still observational.
This design cannot establish causation — the findings describe an association, not a cause. This systematic review includes only one cohort study, two case reports, two animal studies, and eight narrative reviews. No randomized controlled trials are included. The evidence is insufficient to establish causation; only associations or descriptive findings can be inferred.
No Conflicts
No conflicts of interest identified
No conflicts of interest were declared, and no funding sources were reported. The review followed systematic methodology with quality assessment.
Independent Analysis Safeguards
- Used PRISMA 2020 guidelines
- Quality assessment tools: NOS for cohort, JBI for case reports, SYRCLE for animal studies, SANRA 2 for narrative reviews
- Explicit inclusion/exclusion criteria
- Duplicate removal and systematic search across multiple databases
No author disclosures or funding information provided. The review appears to be conducted without apparent industry involvement.
Key takeaways
- 01
In mice with Alzheimer's, FMT reduced harmful brain plaques and improved memory.
- 02
In two elderly patients, memory and thinking tests (MMSE) improved from mild impairment to normal scores (20 to 26 and 29 out of 30).
- 03
The improvements in mice are promising, but mouse studies don't always apply to humans.
- 04
The two human cases are very few, and we need larger, controlled studies to know if FMT really works for Alzheimer's.
Surprising findings
- Two elderly Alzheimer's patients regained normal cognitive scores after receiving a fecal transplant from a healthy donor.Conventional wisdom says Alzheimer's is irreversible, yet these patients' MMSE scores returned to normal (26–29/30) within months.
- FMT reduced Alzheimer's hallmark plaques and tangles in mice.We usually think of Alzheimer's as a brain disease alone, but this shows it may be influenced by gut bacteria.
Practical takeaways
You can't get FMT for Alzheimer's yet, but you can support your gut microbiome with a high-fiber diet and probiotics to boost SCFA production.
FMT is a medical procedure not approved for Alzheimer's; diet changes are low-risk but not proven to prevent or treat the disease.
low confidenceIf you're a caregiver, discuss gut health with the patient's doctor and monitor for any digestive issues that might affect cognition.
No direct evidence that improving gut health changes Alzheimer's outcomes in humans.
low confidenceWhy this study matters
Two case reports: Alzheimer's patients regained normal cognition
An 82-year-old man's MMSE score jumped from 20 (mild impairment) to 26 (normal) two months after FMT from his wife, and reached 29 at four months. A 90-year-old woman with severe C. diff infection also showed improved cognition after FMT from a 27-year-old male.
These are rare examples of reversing dementia-like symptoms with a simple gut treatment, giving hope to millions.
Mice studies: FMT reduced Alzheimer's brain plaques
In APPswe/PS1dE9 transgenic mice, FMT reduced brain amyloid-beta deposition and Tau protein phosphorylation, and improved cognitive function and synaptic plasticity.
This provides a plausible mechanism for how gut bacteria might slow Alzheimer's progression.
The gut-brain axis: from diet to dementia
The review explains how gut bacteria produce short-chain fatty acids (SCFAs) like butyrate, which protect the blood-brain barrier and reduce inflammation. FMT restores SCFA levels.
Connects everyday gut health to brain health, empowering people to take preventive steps.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Alzheimer's disease is a brain problem that gets worse over time. Some scientists think that the bacteria in our gut (the 'gut microbiome') might affect the brain. They studied whether putting healthy poop from a donor into an Alzheimer's patient (called FMT) could help. This review looked at 13 studies, mostly in mice and a few people.
Research results
In mice with Alzheimer's, FMT reduced harmful brain plaques and improved memory. In two elderly patients, memory and thinking tests (MMSE) improved from mild impairment to normal scores (20 to 26 and 29 out of 30).
What this means - more context
The improvements in mice are promising, but mouse studies don't always apply to humans. The two human cases are very few, and we need larger, controlled studies to know if FMT really works for Alzheimer's.
To identify and summarize the effects of fecal microbiota transplantation (FMT) on Alzheimer's disease symptoms through a systematic review of available evidence.
This systematic review of 13 studies (1 cohort, 2 case reports, 2 animal studies, 8 narrative reviews) found that FMT positively affects Alzheimer's disease symptoms in both animal models and human case reports, improving cognitive function as measured by MMSE. However, the authors emphasize the need for randomized controlled trials for conclusive evidence.
Methods Used
Systematic review following PRISMA 2020 guidelines; search of Google Scholar, PubMed, PMC, and ScienceDirect; included English-language studies from past 10 years; quality assessment using study-appropriate tools (NOS, JBI, SYRCLE, SANRA 2); 13 studies scored >70% and were included.
Main Finding
FMT improved Alzheimer's symptoms in mice (reduced amyloid-beta and Tau phosphorylation, improved cognition) and in two human case reports (MMSE increase from 20 to 26-29). However, evidence is limited to animal studies and case reports; no clinical trials available.
Confidence Level
Low to moderate; based primarily on animal studies and case reports, with no randomized controlled trials. The review's conclusions are tentative.
Study Flags
Red Flags
- •Only English-language studies and four databases used, possibly missing relevant research
- •Most evidence from animal studies (2) and narrative reviews (8), with only 2 human case reports
- •No randomized controlled trials available; high risk of selection and publication bias
Surprising Findings
Two elderly Alzheimer's patients regained normal cognitive scores after receiving a fecal transplant from a healthy donor.
Conventional wisdom says Alzheimer's is irreversible, yet these patients' MMSE scores returned to normal (26–29/30) within months.
Practical Takeaways
You can't get FMT for Alzheimer's yet, but you can support your gut microbiome with a high-fiber diet and probiotics to boost SCFA production.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 528 / 100
Probability of being correct
Systematic reviews and meta-analyses of cohort studies. They sit above a single cohort study but below a single randomized trial, because the underlying evidence is still observational.
Systematic Review
Subject
Lower probability
on the GRADE evidence scale
Imagine you hear stories about a new treatment helping some mice and two people feel better. That's what this study is—a collection of stories. It might suggest the treatment could help, but it's not a strong proof because there's no big experiment. So we can say 'it might help' but not 'it definitely helps'.
The study has a COI section but no disclosure was found. A small penalty has been applied.
Strengths
- Systematic search following PRISMA 2020 guidelines
- Quality assessment using validated tools (NOS, JBI, SYRCLE, SANRA 2)
- Clear inclusion/exclusion criteria
Weaknesses
- Inclusion of 8 narrative reviews (low evidence level)
- Only one cohort study and two case reports
- Animal studies not directly translatable to humans
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Alzheimer's disease is a brain problem that gets worse over time. Some scientists think that the bacteria in our gut (the 'gut microbiome') might affect the brain. They studied whether putting healthy poop from a donor into an Alzheimer's patient (called FMT) could help. This review looked at 13 studies, mostly in mice and a few people.
Research results
In mice with Alzheimer's, FMT reduced harmful brain plaques and improved memory. In two elderly patients, memory and thinking tests (MMSE) improved from mild impairment to normal scores (20 to 26 and 29 out of 30).
What this means - more context
The improvements in mice are promising, but mouse studies don't always apply to humans. The two human cases are very few, and we need larger, controlled studies to know if FMT really works for Alzheimer's.
To identify and summarize the effects of fecal microbiota transplantation (FMT) on Alzheimer's disease symptoms through a systematic review of available evidence.
This systematic review of 13 studies (1 cohort, 2 case reports, 2 animal studies, 8 narrative reviews) found that FMT positively affects Alzheimer's disease symptoms in both animal models and human case reports, improving cognitive function as measured by MMSE. However, the authors emphasize the need for randomized controlled trials for conclusive evidence.
Methods Used
Systematic review following PRISMA 2020 guidelines; search of Google Scholar, PubMed, PMC, and ScienceDirect; included English-language studies from past 10 years; quality assessment using study-appropriate tools (NOS, JBI, SYRCLE, SANRA 2); 13 studies scored >70% and were included.
Main Finding
FMT improved Alzheimer's symptoms in mice (reduced amyloid-beta and Tau phosphorylation, improved cognition) and in two human case reports (MMSE increase from 20 to 26-29). However, evidence is limited to animal studies and case reports; no clinical trials available.
Confidence Level
Low to moderate; based primarily on animal studies and case reports, with no randomized controlled trials. The review's conclusions are tentative.
Study Flags
Red Flags
- •Only English-language studies and four databases used, possibly missing relevant research
- •Most evidence from animal studies (2) and narrative reviews (8), with only 2 human case reports
- •No randomized controlled trials available; high risk of selection and publication bias
Surprising Findings
Two elderly Alzheimer's patients regained normal cognitive scores after receiving a fecal transplant from a healthy donor.
Conventional wisdom says Alzheimer's is irreversible, yet these patients' MMSE scores returned to normal (26–29/30) within months.
Practical Takeaways
You can't get FMT for Alzheimer's yet, but you can support your gut microbiome with a high-fiber diet and probiotics to boost SCFA production.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 528 / 100
Probability of being correct
Systematic reviews and meta-analyses of cohort studies. They sit above a single cohort study but below a single randomized trial, because the underlying evidence is still observational.
Systematic Review
Subject
Lower probability
on the GRADE evidence scale
Imagine you hear stories about a new treatment helping some mice and two people feel better. That's what this study is—a collection of stories. It might suggest the treatment could help, but it's not a strong proof because there's no big experiment. So we can say 'it might help' but not 'it definitely helps'.
The study has a COI section but no disclosure was found. A small penalty has been applied.
Strengths
- Systematic search following PRISMA 2020 guidelines
- Quality assessment using validated tools (NOS, JBI, SYRCLE, SANRA 2)
- Clear inclusion/exclusion criteria
Weaknesses
- Inclusion of 8 narrative reviews (low evidence level)
- Only one cohort study and two case reports
- Animal studies not directly translatable to humans
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The researchers looked for all the stories carefully, but most of them are not very reliable—like stories from mice or just two people. That means we can't trust the results very much. We need bigger studies with more people to be sure.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
0 / 100
- Randomizationnot randomized
- Blindingnot blinded
- Control groupno control group
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 528 / 100
Probability of being correct
Systematic reviews and meta-analyses of cohort studies. They sit above a single cohort study but below a single randomized trial, because the underlying evidence is still observational.
This design cannot establish causation — the findings describe an association, not a cause. This systematic review includes only one cohort study, two case reports, two animal studies, and eight narrative reviews. No randomized controlled trials are included. The evidence is insufficient to establish causation; only associations or descriptive findings can be inferred.
No Conflicts
No conflicts of interest identified
No conflicts of interest were declared, and no funding sources were reported. The review followed systematic methodology with quality assessment.
Independent Analysis Safeguards
- Used PRISMA 2020 guidelines
- Quality assessment tools: NOS for cohort, JBI for case reports, SYRCLE for animal studies, SANRA 2 for narrative reviews
- Explicit inclusion/exclusion criteria
- Duplicate removal and systematic search across multiple databases
No author disclosures or funding information provided. The review appears to be conducted without apparent industry involvement.